HK Stock Movement | VISEN PHARMA-B (02561) Surges Over 12% Again as Lonapegsomatropin Nears Approval; Company Recently Enters Strategic Partnership with Tofflon

Stock News12-02

VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed progress in its collaboration with VISEN PHARMA-B, indicating that lonapegsomatropin, a long-acting growth hormone, is nearing approval. On July 14, Anke Biotechnology announced a strategic cooperation framework agreement with VISEN PHARMA-B to jointly promote lonapegsomatropin in the Chinese market. Notably, on November 6 during the 8th China International Import Expo, VISEN PHARMA-B entered into a strategic partnership with Tofflon Science and Technology Group Co., Ltd., a leading domestic pharmaceutical equipment manufacturer, for dual-chamber lyophilized formulation technology. Additionally, the company signed an industrial collaboration agreement with the Lingang New Area Administrative Committee and the Lingang Group's trade platform, marking further progress in its "Global Innovation, China Acceleration" strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189074067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 11:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189074067","market":"sh","top_or_hot":-1,"title":"HK Stock Movement | VISEN PHARMA-B (02561) Surges Over 12% Again as Lonapegsomatropin Nears Approval; Company Recently Enters Strategic Partnership with Tofflon","media":"Stock News","content":"<p>VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed progress in its collaboration with VISEN PHARMA-B, indicating that lonapegsomatropin, a long-acting growth hormone, is nearing approval. On July 14, Anke Biotechnology announced a strategic cooperation framework agreement with VISEN PHARMA-B to jointly promote lonapegsomatropin in the Chinese market. Notably, on November 6 during the 8th China International Import Expo, VISEN PHARMA-B entered into a strategic partnership with Tofflon Science and Technology Group Co., Ltd., a leading domestic pharmaceutical equipment manufacturer, for dual-chamber lyophilized formulation technology. Additionally, the company signed an industrial collaboration agreement with the Lingang New Area Administrative Committee and the Lingang Group's trade platform, marking further progress in its \"Global Innovation, China Acceleration\" strategy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | VISEN PHARMA-B (02561) Surges Over 12% Again as Lonapegsomatropin Nears Approval; Company Recently Enters Strategic Partnership with Tofflon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | VISEN PHARMA-B (02561) Surges Over 12% Again as Lonapegsomatropin Nears Approval; Company Recently Enters Strategic Partnership with Tofflon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-02 11:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed progress in its collaboration with VISEN PHARMA-B, indicating that lonapegsomatropin, a long-acting growth hormone, is nearing approval. On July 14, Anke Biotechnology announced a strategic cooperation framework agreement with VISEN PHARMA-B to jointly promote lonapegsomatropin in the Chinese market. Notably, on November 6 during the 8th China International Import Expo, VISEN PHARMA-B entered into a strategic partnership with Tofflon Science and Technology Group Co., Ltd., a leading domestic pharmaceutical equipment manufacturer, for dual-chamber lyophilized formulation technology. Additionally, the company signed an industrial collaboration agreement with the Lingang New Area Administrative Committee and the Lingang Group's trade platform, marking further progress in its \"Global Innovation, China Acceleration\" strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0251","symbol_name":"专用设备","start_time":0,"source_url":"","article_id":"1189074067","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189074067","pubTimestamp":1764645014,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300171":"东富龙","BK0251":"专用设备","BK1161":"生物科技","02561":"维昇药业-B"},"translate_title":"港股动向|维森制药-B(02561)再升逾12%，因Lonapegsomatropin接近获批；公司最近与东富龙建立战略合作伙伴关系","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300171":1,"02561":1},"content_text":"VISEN PHARMA-B (02561) surged over 12% again, rising 7.11% to HKD 35.26 by the time of writing, with a turnover of HKD 1.9082 million. On the news front, Anke Biotechnology recently disclosed progress in its collaboration with VISEN PHARMA-B, indicating that lonapegsomatropin, a long-acting growth hormone, is nearing approval. On July 14, Anke Biotechnology announced a strategic cooperation framework agreement with VISEN PHARMA-B to jointly promote lonapegsomatropin in the Chinese market. Notably, on November 6 during the 8th China International Import Expo, VISEN PHARMA-B entered into a strategic partnership with Tofflon Science and Technology Group Co., Ltd., a leading domestic pharmaceutical equipment manufacturer, for dual-chamber lyophilized formulation technology. Additionally, the company signed an industrial collaboration agreement with the Lingang New Area Administrative Committee and the Lingang Group's trade platform, marking further progress in its \"Global Innovation, China Acceleration\" strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189074067","isCrawlerRequest":true}